Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD

The Medical News ·
Health & Medicine United Kingdom

Richmond Pharmacology, a specialist early-phase clinical research organization, has announced encouraging results from a first-in-human clinical trial evaluating CIDEBsiRNA, an investigational RNA interference (RNAi) therapy developed by Regeneron Pharmaceuticals, Inc.

Read original article on The Medical News →

Related news